Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study

被引：0
|
作者：
Avram Goldberg
Thomas Geppert
Elena Schiopu
Tracy Frech
Vivien Hsu
Robert W Simms
Stanford L Peng
Yihong Yao
Nairouz Elgeioushi
Linda Chang
Bing Wang
Stephen Yoo
机构：
[1] Hofstra North Shore-LIJ School of Medicine,North Shore LIJ Health Systems and Division of Rheumatology
[2] Metroplex Clinical Research Center,undefined
[3] LLC,undefined
[4] University of Michigan,undefined
[5] University of Utah,undefined
[6] RWJ Medical School Clinical Research Center,undefined
[7] Boston University School Of Medicine,undefined
[8] Benaroya Research Institute at Virginia Mason Medical Center,undefined
[9] MedImmune,undefined
[10] MedImmune,undefined
来源：
Arthritis Research & Therapy | / 16卷
关键词：
Human Papilloma Virus; Chronic Myelogenous Leukemia; Evaluable Population; Positive Baseline; Minimum Anticipate Biological Effect Level;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
    Goldberg, Avram
    Geppert, Thomas
    Schiopu, Elena
    Frech, Tracy
    Hsu, Vivien
    Simms, Robert W.
    Peng, Stanford L.
    Yao, Yihong
    Elgeioushi, Nairouz
    Chang, Linda
    Wang, Bing
    Yoo, Stephen
    ARTHRITIS RESEARCH & THERAPY, 2014, 16 (01)
  • [2] A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma
    Goldberg, Avram Z.
    Geppert, Thomas D.
    Schiopu, Elena
    Frech, Tracy M.
    Hsu, Vivien M.
    Simms, Robert W.
    Peng, Stanford L.
    Yao, Yihong
    Elgeioushi, Nairouz
    Wang, Bing
    Chang, Linda
    Yoo, Stephen
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S297 - S297
  • [3] Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study
    Takeuchi, Tsutomu
    Tanaka, Yoshiya
    Matsumura, Ryutaro
    Saito, Kazuyoshi
    Yoshimura, Mitsuhiro
    Amano, Koichi
    Atsumi, Tatsuya
    Suematsu, Eiichi
    Hayashi, Nobuya
    Wang, Liangwei
    Tummala, Raj
    MODERN RHEUMATOLOGY, 2020, 30 (01) : 93 - 100
  • [4] A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
    von Mehren, Margaret
    Britten, Carolyn D.
    Pieslor, Peter
    Saville, Wayne
    Vassos, Artemios
    Harris, Sarah
    Galluppi, Gerald R.
    Darif, Mohamed
    Wainberg, Zev A.
    Cohen, Roger B.
    Leong, Stephen
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 518 - 525
  • [5] A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
    Margaret von Mehren
    Carolyn D. Britten
    Peter Pieslor
    Wayne Saville
    Artemios Vassos
    Sarah Harris
    Gerald R. Galluppi
    Mohamed Darif
    Zev A. Wainberg
    Roger B. Cohen
    Stephen Leong
    Investigational New Drugs, 2014, 32 : 518 - 525
  • [6] A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD
    Nowak, Kristen L.
    Kakkar, Rahul
    Devalaraja, Matt
    Lo, Larry
    Park, Wansu
    Gobburu, Joga
    Kling, Douglas
    Davidson, Michael
    Chonchol, Michel
    KIDNEY360, 2021, 2 (02): : 224 - 235
  • [7] Anifrolumab Anti-interferon-α receptor 1(IFNAR1) monoclonal antibody Treatment of systemic lupus erythematosus
    Haddley, K.
    DRUGS OF THE FUTURE, 2018, 43 (07) : 471 - 481
  • [8] A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
    Becerra, Carlos R.
    Conkling, Paul
    Vogelzang, Nicholas
    Wu, Hilary
    Hong, Shengyan
    Narwal, Rajesh
    Liang, Meina
    Tavakkoli, Fatemeh
    Pandya, Naimish
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 917 - 925
  • [9] A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
    Carlos R. Becerra
    Paul Conkling
    Nicholas Vogelzang
    Hilary Wu
    Shengyan Hong
    Rajesh Narwal
    Meina Liang
    Fatemeh Tavakkoli
    Naimish Pandya
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 917 - 925
  • [10] A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies
    Olszewski, Adam
    Kahn, David
    Yoo, Brian
    Tan, Joanne B. L.
    Gupta, Vipul K.
    Schuck, Edgar
    Nie, Zhe
    Krilov, Goran
    Wright, D. Hamish
    Weiss, Daniel
    Lachowicz, Jean
    Akinsanya, Karen
    Yin, Wu
    BLOOD, 2023, 142
12345